Integra LifeSciences (IART) Financials

$14.27 -0.59 (-3.97%)

Closing price 04:00 PM Eastern

Extended Trading

$14.28 +0.02 (+0.11%)

As of 06:07 PM Eastern

Annual Income Statements for Integra LifeSciences

This table shows Integra LifeSciences' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Period end date	12/31/2014	12/31/2015	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024
Net Income / (Loss) Attributable to Common Shareholders	34	-3.52	75	65	61	50	134	169	181	68	-6.94
Consolidated Net Income / (Loss)	34	-3.52	75	65	61	50	134	169	181	68	-6.94
Net Income / (Loss) Continuing Operations	36	6.85	75	65	61	50	134	169	181	68	-6.94
Total Pre-Tax Income	46	61	90	11	57	60	94	215	214	81	-18
Total Operating Income	68	80	115	45	111	94	151	197	239	112	28
Total Gross Profit	494	556	643	753	901	953	851	945	970	885	882
Total Revenue	797	883	992	1,188	1,472	1,518	1,372	1,542	1,558	1,542	1,611
Operating Revenue	797	883	992	1,188	1,472	1,518	1,372	1,542	1,558	1,542	1,611
Total Cost of Revenue	303	327	349	436	571	565	521	598	587	657	728
Operating Cost of Revenue	303	327	349	436	571	565	521	598	587	657	728
Total Operating Expenses	426	477	528	708	790	859	700	747	731	773	854
Selling, General & Admin Expense	376	416	456	624	691	688	595	637	616	657	717
Research & Development Expense	44	51	58	63	78	144	77	93	101	104	115
Amortization Expense	6.81	9.95	14	20	21	27	28	17	14	12	21
Total Other Income / (Expense), net	-22	-19	-25	-33	-54	-34	-58	17	-25	-30	-47
Interest Expense	22	24	26	35	65	54	72	50	50	51	71
Interest & Investment Income	0.17	0.03	0.02	0.26	2.80	11	9.30	6.74	12	17	20
Other Income / (Expense), net	-0.49	4.59	0.85	1.35	8.29	9.52	4.43	61	13	3.72	3.94
Income Tax Expense	9.27	54	16	-53	-3.40	9.90	-40	46	33	13	-11
Basic Earnings per Share	$0.52	($0.05)	$1.00	$0.84	$0.73	$0.59	$1.58	$2.00	$2.18	$0.85	($0.09)
Weighted Average Basic Shares Outstanding	64.86M	68.99M	74.39M	76.90M	82.86M	85.64M	84.65M	84.70M	83.00M	80.09M	77.01M
Diluted Earnings per Share	$0.52	($0.05)	$0.94	$0.82	$0.72	$0.58	$1.57	$1.98	$2.16	$0.84	($0.09)
Weighted Average Diluted Shares Outstanding	65.92M	71.35M	79.19M	79.12M	84.00M	86.49M	85.23M	85.49M	83.52M	80.34M	77.01M
Weighted Average Basic & Diluted Shares Outstanding	32.40M	70.40M	74.60M	77.10M	83.30M	84.44M	84.37M	83.24M	81.64M	78.22M	77.22M

This table shows Integra LifeSciences' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025
Period end date	12/31/2022	3/31/2023	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025
Net Income / (Loss) Attributable to Common Shareholders	53	24	4.18	19	20	-3.28	-12	-11	19	-25	-484
Consolidated Net Income / (Loss)	53	24	4.18	19	20	-3.28	-12	-11	19	-25	-484
Net Income / (Loss) Continuing Operations	53	24	4.18	19	20	-3.28	-12	-11	19	-25	-484
Total Pre-Tax Income	64	30	3.82	19	29	-5.23	-15	-20	23	-30	-531
Total Operating Income	68	36	13	27	36	3.96	-3.03	-8.15	36	-15	-513
Total Gross Profit	250	233	207	218	226	207	226	200	249	194	209
Total Revenue	398	381	381	382	397	369	418	381	443	383	416
Operating Revenue	398	381	381	382	397	369	418	381	443	383	416
Total Cost of Revenue	148	148	174	164	171	162	192	181	194	188	206
Operating Cost of Revenue	148	148	174	164	171	162	192	181	194	188	206
Total Operating Expenses	182	196	195	192	190	203	229	208	213	210	722
Selling, General & Admin Expense	152	167	165	162	163	166	195	177	179	181	180
Research & Development Expense	27	27	27	27	24	27	30	27	31	25	27
Amortization Expense	3.54	3.11	3.03	3.21	3.03	10	3.71	3.76	3.72	3.70	3.75
Impairment Charge	-	-	-	-	-	-	0.00	-	-	-	511
Total Other Income / (Expense), net	-3.63	-6.60	-8.68	-7.98	-7.19	-9.19	-12	-12	-13	-15	-18
Interest Expense	13	12	12	13	14	14	19	19	19	19	21
Interest & Investment Income	5.31	4.11	3.94	4.61	4.55	5.04	5.06	5.05	4.89	4.42	4.71
Other Income / (Expense), net	3.95	1.39	-0.16	0.47	2.01	-0.61	1.44	2.11	1.01	-0.14	-1.95
Income Tax Expense	11	5.55	-0.36	-0.89	9.02	-1.95	-2.78	-9.67	3.11	-4.74	-47
Basic Earnings per Share	$0.65	$0.30	$0.05	$0.24	$0.26	($0.04)	($0.16)	($0.14)	$0.25	($0.33)	($6.31)
Weighted Average Basic Shares Outstanding	83.00M	81.87M	80.97M	79.69M	80.09M	77.74M	77.41M	76.45M	77.01M	76.46M	76.70M
Diluted Earnings per Share	$0.63	$0.29	$0.05	$0.24	$0.26	($0.04)	($0.16)	($0.14)	$0.25	($0.33)	($6.31)
Weighted Average Diluted Shares Outstanding	83.52M	82.32M	81.15M	79.81M	80.34M	77.74M	77.41M	76.45M	77.01M	76.46M	76.70M
Weighted Average Basic & Diluted Shares Outstanding	81.64M	81.90M	81.40M	78.18M	78.22M	78.80M	77.58M	77.16M	77.22M	77.71M	77.91M

This table details how cash moves in and out of Integra LifeSciences' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Period end date	12/31/2014	12/31/2015	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024
Net Change in Cash & Equivalents	-49	-24	54	73	-31	60	271	43	-57	-180	-30
Net Cash From Operating Activities	84	105	116	115	200	231	204	312	264	140	129
Net Cash From Continuing Operating Activities	63	117	116	115	200	231	204	312	264	140	129
Net Income / (Loss) Continuing Operations	36	6.85	75	65	61	50	134	169	181	68	-6.94
Consolidated Net Income / (Loss)	34	-3.52	75	65	61	50	134	169	181	68	-6.94
Depreciation Expense	46	59	73	89	111	109	116	120	118	124	141
Amortization Expense	2.57	2.26	2.53	2.72	6.27	5.39	12	-	6.85	6.16	5.59
Non-Cash Adjustments To Reconcile Net Income	23	60	-16	31	27	99	46	10	23	23	47
Changes in Operating Assets and Liabilities, net	-45	-11	-18	-73	-5.22	-32	-105	13	-64	-81	-58
Net Cash From Investing Activities	-363	-372	-43	-1,221	-50	-163	-68	-161	-59	-94	-391
Net Cash From Continuing Investing Activities	-360	-365	-43	-1,221	-50	-163	-68	-161	-59	-94	-391
Purchase of Property, Plant & Equipment	-38	-33	-47	-44	-78	-70	-39	-48	-42	-67	-104
Acquisitions	-321	-329	-	-1,242	0.00	-96	-25	-304	-56	0.00	-288
Purchase of Investments	-	-	-	-	0.00	1.58	-7.84	0.00	4.91	-27	-53
Sale of Property, Plant & Equipment	0.00	1.44	0.32	0.29	0.42	0.04	3.66	0.00	11	0.00	0.00
Divestitures	-	0.00	0.00	46	27	0.00	0.00	190	24	0.00	0.00
Sale and/or Maturity of Investments	-	0.00	0.00	17	0.91	0.75	-	0.08	0.00	0.00	55
Net Cash From Financing Activities	239	248	-15	1,169	-181	-8.77	122	-98	-252	-230	238
Net Cash From Continuing Financing Activities	239	295	-15	1,169	-181	-8.77	122	-98	-252	-230	238
Repayment of Debt	-199	-470	-701	-136	-665	-246	-465	-126	-149	-118	-187
Repurchase of Common Equity	-	-	-	-	0.00	0.00	-100	0.00	-125	-275	-52
Issuance of Debt	425	545	680	1,307	171	237	747	26	41	165	487
Other Financing Activities, net	12	0.72	5.63	-2.01	-37	0.43	-104	2.02	-19	-1.55	-9.04
Other Net Changes in Cash	-	-	-	11	-	0.07	-	-	-11	3.89	-6.46

This table details how cash moves in and out of Integra LifeSciences' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025
Period end date	12/31/2022	3/31/2023	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025
Net Change in Cash & Equivalents	-55	-149	1.83	-35	2.67	316	-377	-0.08	31	-7.27	-21
Net Cash From Operating Activities	85	26	28	27	59	16	40	22	51	-11	8.92
Net Cash From Continuing Operating Activities	85	26	28	27	59	16	40	22	51	-11	8.92
Net Income / (Loss) Continuing Operations	53	24	4.18	19	20	-3.28	-12	-11	19	-25	-484
Consolidated Net Income / (Loss)	53	24	4.18	19	20	-3.28	-12	-11	19	-25	-484
Depreciation Expense	29	31	31	31	31	31	37	36	38	37	38
Amortization Expense	1.70	1.89	1.42	1.42	1.43	1.40	1.46	1.34	1.40	1.39	1.89
Non-Cash Adjustments To Reconcile Net Income	-2.22	4.86	5.68	5.93	6.64	13	14	3.66	17	2.11	516
Changes in Operating Assets and Liabilities, net	3.41	-36	-14	-31	-0.15	-26	0.44	-7.77	-24	-27	-63
Net Cash From Investing Activities	-55	-14	-16	-7.70	-57	-54	-322	-10	-4.25	-36	-22
Net Cash From Continuing Investing Activities	-55	-14	-16	-7.70	-57	-54	-322	-10	-4.25	-36	-22
Purchase of Property, Plant & Equipment	-14	-14	-16	-13	-25	-15	-30	-30	-30	-29	-20
Purchase of Investments	-	0.00	-	5.38	-33	-39	-10	-	-4.13	-7.00	-1.50
Net Cash From Financing Activities	-98	-163	-11	-50	-6.89	359	-94	-20	-7.15	35	-21
Net Cash From Continuing Financing Activities	-98	-163	-11	-50	-6.89	359	-94	-20	-7.15	35	-21
Repayment of Debt	-108	-20	-17	-57	-25	-15	-91	-42	-40	-15	-20
Issuance of Debt	6.50	10	5.00	132	18	371	59	22	35	54	13
Other Financing Activities, net	3.60	-2.91	1.01	0.44	-0.09	3.28	-12	-0.17	-0.14	-3.78	-14
Other Net Changes in Cash	12	0.94	-0.21	-4.87	8.04	-4.96	-1.13	7.75	-8.12	4.53	13

This table presents Integra LifeSciences' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Period end date	12/31/2014	12/31/2015	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024
Total Assets	1,587	1,774	1,808	3,211	3,108	3,303	3,615	3,782	3,890	3,782	4,037
Total Current Assets	529	438	495	822	775	858	1,237	1,154	1,161	1,058	1,082
Cash & Equivalents	72	48	102	175	139	199	470	513	457	276	246
Short-Term Investments	-	-	-	-	-	-	-	-	0.00	33	27
Accounts Receivable	110	132	148	252	266	275	226	232	263	259	272
Inventories, net	189	211	217	296	280	316	310	317	325	390	429
Prepaid Expenses	28	43	28	99	90	68	69	91	86	67	77
Other Current Assets	-	-	-	-	-	-	-	-	31	33	30
Plant, Property, & Equipment, net	194	205	222	269	300	337	288	312	311	340	406
Total Noncurrent Assets	864	1,131	1,090	2,120	2,033	2,108	2,090	2,317	2,417	2,384	2,550
Goodwill	363	512	511	938	926	954	932	1,013	1,039	1,055	1,097
Intangible Assets	413	604	561	1,160	1,079	1,032	989	1,146	1,127	1,068	1,208
Noncurrent Deferred & Refundable Income Taxes	4.47	6.93	6.94	6.25	6.81	13	74	57	46	46	35
Other Noncurrent Operating Assets	10	7.49	12	16	20	109	95	101	205	214	211
Total Liabilities & Shareholders' Equity	1,587	1,774	1,808	3,211	3,108	3,303	3,615	3,782	3,890	3,782	4,037
Total Liabilities	883	1,023	968	2,249	1,732	1,887	2,100	2,098	2,085	2,194	2,492
Total Current Liabilities	126	139	124	349	263	331	401	340	321	307	922
Short-Term Debt	3.75	14	0.00	83	23	45	146	45	38	15	607
Accounts Payable	29	35	29	94	76	113	55	62	102	92	83
Accrued Expenses	40	39	35	88	85	77	94	120	80	101	122
Current Deferred Revenue	5.18	5.67	6.81	11	3.76	4.77	5.28	-	-	-	10
Current Employee Benefit Liabilities	35	45	53	73	76	79	76	93	79	75	86
Other Current Liabilities	-	-	-	-	-	12	13	20	22	24	15
Total Noncurrent Liabilities	757	884	845	1,900	1,470	1,555	1,699	1,758	1,764	1,887	1,570
Long-Term Debt	626	700	665	1,781	1,332	1,303	1,408	1,501	1,405	1,485	1,196
Noncurrent Deferred & Payable Income Tax Liabilities	100	155	149	65	58	37	16	46	63	35	61
Other Noncurrent Operating Liabilities	28	29	31	54	80	216	275	120	139	200	313
Total Equity & Noncontrolling Interests	704	751	840	962	1,376	1,417	1,515	1,685	1,804	1,588	1,545
Total Preferred & Common Equity	704	751	840	962	1,376	1,417	1,515	1,685	1,804	1,588	1,545
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	704	751	840	962	1,376	1,417	1,515	1,685	1,804	1,588	1,545
Common Stock	780	1,021	799	823	1,193	1,215	1,292	1,266	1,278	1,303	1,324
Retained Earnings	315	146	220	285	348	399	532	699	879	947	940
Treasury Stock	-367	-367	-123	-122	-121	-120	-235	-234	-363	-647	-691
Accumulated Other Comprehensive Income / (Loss)	-23	-48	-57	-24	-45	-76	-74	-45	10	-15	-28

This table presents Integra LifeSciences' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q2 2022	Q3 2022	Q1 2023	Q2 2023	Q3 2023	Q1 2024	Q2 2024	Q3 2024	Q1 2025	Q2 2025
Period end date	6/30/2022	9/30/2022	3/31/2023	6/30/2023	9/30/2023	3/31/2024	6/30/2024	9/30/2024	3/31/2025	6/30/2025
Total Assets	3,753	3,807	3,742	3,778	3,739	4,078	4,074	4,066	4,053	3,668
Total Current Assets	1,137	1,196	1,029	1,051	1,027	1,416	1,112	1,100	1,107	1,143
Cash & Equivalents	447	512	307	309	274	592	215	215	239	218
Short-Term Investments	-	-	-	-	-	71	82	62	34	36
Accounts Receivable	237	248	254	259	256	241	271	248	252	285
Inventories, net	320	311	351	354	366	403	422	437	445	465
Prepaid Expenses	102	123	117	129	131	73	94	86	104	103
Other Current Assets	31	1.83	-	-	-	35	29	50	32	36
Plant, Property, & Equipment, net	302	301	315	318	319	345	374	391	423	435
Total Noncurrent Assets	2,313	2,310	2,398	2,409	2,393	2,317	2,589	2,575	2,523	2,090
Goodwill	990	978	1,042	1,043	1,036	1,040	1,105	1,117	1,105	616
Intangible Assets	1,082	1,054	1,109	1,094	1,067	1,023	1,220	1,210	1,188	1,188
Noncurrent Deferred & Refundable Income Taxes	47	52	45	56	56	34	46	49	38	103
Other Noncurrent Operating Assets	193	226	203	216	235	220	218	200	192	183
Total Liabilities & Shareholders' Equity	3,753	3,807	3,742	3,778	3,739	4,078	4,074	4,066	4,053	3,668
Total Liabilities	2,092	2,083	2,067	2,094	2,160	2,480	2,540	2,544	2,529	2,629
Total Current Liabilities	296	304	282	377	356	302	328	913	918	930
Short-Term Debt	51	56	0.00	96	85	19	24	602	613	613
Accounts Payable	69	81	113	100	94	94	107	78	91	93
Accrued Expenses	85	79	93	95	90	112	102	132	137	131
Current Employee Benefit Liabilities	70	69	54	65	64	53	70	76	52	67
Other Current Liabilities	13	13	23	23	23	24	25	15	25	25
Total Noncurrent Liabilities	1,796	1,778	1,785	1,717	1,804	2,178	2,212	1,632	1,610	1,699
Long-Term Debt	1,498	1,487	1,440	1,333	1,420	1,837	1,801	1,205	1,231	1,227
Capital Lease Obligations	-	-	157	160	168	170	170	-	161	159
Noncurrent Deferred & Payable Income Tax Liabilities	61	70	62	71	74	31	87	69	58	60
Other Noncurrent Operating Liabilities	237	221	127	153	142	140	155	358	160	253
Total Equity & Noncontrolling Interests	1,661	1,724	1,675	1,683	1,579	1,598	1,534	1,522	1,524	1,039
Total Preferred & Common Equity	1,661	1,724	1,675	1,683	1,579	1,598	1,534	1,522	1,524	1,039
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	1,661	1,724	1,675	1,683	1,579	1,598	1,534	1,522	1,524	1,039
Common Stock	1,261	1,269	1,246	1,285	1,263	1,311	1,302	1,318	1,324	1,329
Retained Earnings	776	826	903	908	927	944	931	920	915	431
Treasury Stock	-363	-363	-482	-514	-613	-646	-681	-692	-690	-690
Accumulated Other Comprehensive Income / (Loss)	-13	-7.44	7.07	4.83	1.75	-11	-19	-25	-24	-31

This table displays calculated financial ratios and metrics derived from Integra LifeSciences' official financial filings.

Metric	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Period end date	12/31/2014	12/31/2015	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	14.33%	10.80%	12.39%	19.77%	23.92%	3.06%	-9.60%	12.43%	0.99%	-1.03%	4.47%
EBITDA Growth	73.97%	24.86%	31.71%	-27.99%	71.45%	-7.68%	30.15%	33.20%	-0.39%	-34.99%	-26.98%
EBIT Growth	100.62%	24.95%	38.03%	-60.28%	158.48%	-13.42%	50.85%	65.81%	-2.62%	-54.19%	-71.92%
NOPAT Growth	30.32%	-83.37%	958.51%	167.83%	-53.86%	-33.39%	176.73%	-28.32%	29.83%	-53.79%	-78.66%
Net Income Growth	261.41%	-110.35%	2,218.90%	-13.17%	-6.09%	-17.43%	166.71%	26.28%	6.79%	-62.48%	-110.25%
EPS Growth	261.41%	-110.35%	2,218.90%	-12.77%	-12.20%	-19.44%	170.69%	26.11%	9.09%	-61.11%	-110.71%
Operating Cash Flow Growth	56.88%	25.48%	11.02%	-1.60%	74.33%	15.90%	-11.93%	53.28%	-15.35%	-47.08%	-7.55%
Free Cash Flow Firm Growth	-356.94%	-162.76%	135.50%	-1,035.49%	117.88%	-41.70%	222.20%	-161.03%	129.98%	58.00%	-386.75%
Invested Capital Growth	17.91%	27.88%	-0.79%	89.03%	-2.27%	-0.98%	-4.56%	14.66%	5.01%	-0.11%	10.07%
Revenue Q/Q Growth	9.84%	11.13%	1.48%	10.50%	1.01%	0.78%	-0.47%	1.11%	-0.48%	-0.06%	2.91%
EBITDA Q/Q Growth	-12.71%	1.85%	9.58%	-13.10%	11.57%	0.63%	5.78%	1.63%	4.12%	-11.72%	2.96%
EBIT Q/Q Growth	-33.50%	-3.82%	16.43%	-39.20%	24.82%	1.14%	12.21%	3.35%	3.85%	-22.64%	-4.23%
NOPAT Q/Q Growth	-37.89%	-43.89%	17.19%	244.04%	-50.58%	-17.25%	130.64%	-24.43%	2.43%	-24.94%	-1.46%
Net Income Q/Q Growth	11.09%	-163.99%	21.64%	33.12%	-24.02%	-16.36%	137.12%	-21.88%	4.37%	-32.83%	-6.11%
EPS Q/Q Growth	11.09%	-163.99%	21.64%	32.26%	-23.40%	-17.14%	134.33%	-21.74%	4.85%	-30.58%	-12.50%
Operating Cash Flow Q/Q Growth	18.70%	0.75%	-14.10%	4.58%	18.48%	25.14%	-4.19%	-3.40%	6.46%	-15.96%	-5.83%
Free Cash Flow Firm Q/Q Growth	26.97%	-52.85%	82.82%	-695.62%	123.51%	21.95%	5.26%	-73.87%	-58.35%	197.97%	-433.12%
Invested Capital Q/Q Growth	-5.41%	2.41%	-0.07%	65.44%	-0.20%	-1.54%	2.77%	3.78%	6.99%	-1.12%	6.27%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	61.98%	63.01%	64.81%	63.35%	61.19%	62.79%	62.03%	61.24%	62.29%	57.39%	54.77%
EBITDA Margin	14.61%	16.46%	19.29%	11.60%	16.05%	14.37%	20.70%	24.52%	24.18%	15.89%	11.10%
Operating Margin	8.52%	9.02%	11.63%	3.77%	7.54%	6.18%	11.03%	12.79%	15.34%	7.23%	1.76%
EBIT Margin	8.46%	9.54%	11.71%	3.88%	8.10%	6.81%	11.36%	16.75%	16.15%	7.48%	2.01%
Profit (Net Income) Margin	4.27%	-0.40%	7.52%	5.45%	4.13%	3.31%	9.76%	10.96%	11.59%	4.39%	-0.43%
Tax Burden Percent	74.63%	-5.80%	82.48%	568.67%	105.92%	83.52%	143.17%	78.76%	84.41%	83.56%	38.08%
Interest Burden Percent	67.64%	72.08%	77.81%	24.67%	48.12%	58.19%	60.02%	83.10%	85.02%	70.35%	-56.37%
Effective Tax Rate	20.35%	88.71%	17.52%	-468.67%	-5.92%	16.48%	-43.17%	21.24%	15.59%	16.44%	0.00%
Return on Invested Capital (ROIC)	5.29%	0.71%	6.76%	12.57%	4.49%	3.04%	8.64%	5.91%	7.01%	3.16%	0.64%
ROIC Less NNEP Spread (ROIC-NNEP)	-0.67%	-1.64%	3.40%	-4.31%	0.58%	0.66%	0.69%	7.25%	5.14%	1.13%	-1.11%
Return on Net Nonoperating Assets (RNNOA)	-0.33%	-1.20%	2.62%	-5.38%	0.72%	0.56%	0.49%	4.66%	3.34%	0.83%	-1.09%
Return on Equity (ROE)	4.96%	-0.48%	9.37%	7.19%	5.20%	3.60%	9.13%	10.57%	10.35%	3.99%	-0.44%
Cash Return on Invested Capital (CROIC)	-11.15%	-23.76%	7.54%	-49.03%	6.78%	4.02%	13.31%	-7.75%	2.12%	3.27%	-8.94%
Operating Return on Assets (OROA)	4.85%	5.01%	6.49%	1.84%	3.78%	3.22%	4.50%	6.98%	6.56%	3.00%	0.83%
Return on Assets (ROA)	2.45%	-0.21%	4.16%	2.58%	1.92%	1.57%	3.87%	4.57%	4.71%	1.77%	-0.18%
Return on Common Equity (ROCE)	4.96%	-0.48%	9.37%	7.19%	5.20%	3.60%	9.13%	10.57%	10.35%	3.99%	-0.44%
Return on Equity Simple (ROE_SIMPLE)	4.83%	-0.47%	8.88%	6.73%	4.42%	3.54%	8.84%	10.04%	10.01%	4.27%	-0.45%
Net Operating Profit after Tax (NOPAT)	54	8.99	95	255	118	78	217	155	202	93	20
NOPAT Margin	6.78%	1.02%	9.59%	21.44%	7.98%	5.16%	15.80%	10.07%	12.95%	6.05%	1.23%
Net Nonoperating Expense Percent (NNEP)	5.96%	2.35%	3.36%	16.88%	3.91%	2.38%	7.95%	-1.34%	1.86%	2.03%	1.76%
Return On Investment Capital (ROIC_SIMPLE)	4.05%	0.61%	6.32%	9.02%	4.31%	2.83%	7.06%	4.68%	5.92%	2.86%	0.57%
Cost of Revenue to Revenue	38.02%	36.99%	35.19%	36.65%	38.81%	37.21%	37.97%	38.76%	37.71%	42.61%	45.23%
SG&A Expenses to Revenue	47.14%	47.10%	45.93%	52.52%	46.91%	45.31%	43.34%	41.33%	39.57%	42.60%	44.52%
R&D to Revenue	5.47%	5.77%	5.86%	5.34%	5.30%	9.52%	5.64%	6.03%	6.50%	6.76%	7.16%
Operating Expenses to Revenue	53.46%	53.99%	53.19%	59.58%	53.65%	56.61%	51.00%	48.46%	46.95%	50.16%	53.00%
Earnings before Interest and Taxes (EBIT)	67	84	116	46	119	103	156	258	252	115	32
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	116	145	191	138	236	218	284	378	377	245	179
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	2.52	3.34	3.82	3.90	2.79	3.53	3.61	3.37	2.60	2.14	1.13
Price to Tangible Book Value (P/TBV)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Price to Revenue (P/Rev)	2.23	2.84	3.23	3.16	2.61	3.30	3.99	3.68	3.01	2.21	1.09
Price to Earnings (P/E)	52.29	0.00	43.01	58.01	63.18	99.68	40.86	33.56	25.94	50.26	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	1.91%	0.00%	2.32%	1.72%	1.58%	1.00%	2.45%	2.98%	3.86%	1.99%	0.00%
Enterprise Value to Invested Capital (EV/IC)	2.11	2.24	2.69	2.05	1.95	2.40	2.68	2.42	1.98	1.62	1.06
Enterprise Value to Revenue (EV/Rev)	2.93	3.59	3.80	4.58	3.43	4.05	4.78	4.41	3.74	3.09	2.14
Enterprise Value to EBITDA (EV/EBITDA)	20.08	21.81	19.70	39.51	21.40	28.21	23.09	17.97	15.47	19.44	19.27
Enterprise Value to EBIT (EV/EBIT)	34.68	37.65	32.45	117.99	42.39	59.58	42.07	26.31	23.16	41.32	106.52
Enterprise Value to NOPAT (EV/NOPAT)	43.23	352.61	39.63	21.37	43.01	78.58	30.25	43.76	28.89	51.10	173.30
Enterprise Value to Operating Cash Flow (EV/OCF)	27.96	30.22	32.39	47.54	25.33	26.59	32.16	21.76	22.03	34.02	26.64
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	35.49	0.00	28.46	59.40	19.64	0.00	95.42	49.36	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.89	0.95	0.79	1.94	0.98	0.95	1.03	0.97	0.89	1.05	1.27
Long-Term Debt to Equity	0.89	0.93	0.79	1.85	0.97	0.92	0.93	0.94	0.87	1.04	0.88
Financial Leverage	0.49	0.73	0.77	1.25	1.24	0.85	0.71	0.64	0.65	0.74	0.97
Leverage Ratio	2.03	2.31	2.25	2.79	2.70	2.30	2.36	2.31	2.20	2.26	2.50
Compound Leverage Factor	1.37	1.66	1.75	0.69	1.30	1.34	1.42	1.92	1.87	1.59	-1.41
Debt to Total Capital	47.21%	48.74%	44.20%	65.95%	49.60%	48.76%	50.65%	49.27%	47.01%	51.21%	56.04%
Short-Term Debt to Total Capital	0.28%	0.98%	0.00%	2.93%	0.82%	1.63%	4.76%	1.35%	1.12%	0.45%	17.27%
Long-Term Debt to Total Capital	46.93%	47.76%	44.20%	63.02%	48.78%	47.13%	45.88%	47.92%	45.89%	50.76%	38.77%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	52.79%	51.26%	55.80%	34.05%	50.40%	51.24%	49.35%	50.73%	52.99%	48.79%	43.96%
Debt to EBITDA	5.41	4.92	3.47	13.52	5.73	6.18	5.48	4.33	4.25	6.80	11.02
Net Debt to EBITDA	4.80	4.56	2.94	12.26	5.14	5.27	3.82	2.97	3.04	5.54	9.49
Long-Term Debt to EBITDA	5.38	4.82	3.47	12.92	5.64	5.97	4.96	4.21	4.15	6.74	7.62
Debt to NOPAT	11.66	79.50	6.99	7.32	11.52	17.21	7.17	10.54	7.94	17.88	99.06
Net Debt to NOPAT	10.33	73.69	5.92	6.63	10.34	14.67	5.00	7.23	5.67	14.56	85.30
Long-Term Debt to NOPAT	11.59	77.90	6.99	6.99	11.33	16.64	6.50	10.25	7.75	17.73	68.53
Altman Z-Score	2.43	2.44	3.17	1.72	2.29	2.51	2.57	2.77	2.54	2.03	1.22
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	4.20	3.15	4.01	2.36	2.95	2.59	3.09	3.39	3.62	3.45	1.17
Quick Ratio	1.45	1.30	2.02	1.22	1.54	1.43	1.73	2.19	2.24	1.85	0.59
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-114	-299	106	-994	178	104	334	-204	61	96	-277
Operating Cash Flow to CapEx	217.96%	327.92%	247.61%	265.09%	258.26%	333.00%	578.53%	650.63%	847.71%	209.31%	123.91%
Free Cash Flow to Firm to Interest Expense	-5.18	-12.72	4.12	-28.38	2.75	1.92	4.66	-4.04	1.23	1.88	-3.92
Operating Cash Flow to Interest Expense	3.80	4.46	4.51	3.27	3.09	4.29	2.85	6.20	5.33	2.72	1.83
Operating Cash Flow Less CapEx to Interest Expense	2.06	3.10	2.69	2.04	1.89	3.00	2.36	5.25	4.70	1.42	0.35
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.57	0.53	0.55	0.47	0.47	0.47	0.40	0.42	0.41	0.40	0.41
Accounts Receivable Turnover	6.97	7.28	7.08	5.94	5.69	5.61	5.48	6.75	6.29	5.90	6.06
Inventory Turnover	1.53	1.63	1.63	1.70	1.98	1.89	1.66	1.91	1.83	1.84	1.78
Fixed Asset Turnover	4.04	4.43	4.64	4.83	5.17	4.76	4.39	5.15	5.00	4.73	4.32
Accounts Payable Turnover	7.61	10.26	10.94	7.08	6.72	5.97	6.21	10.27	7.17	6.76	8.33
Days Sales Outstanding (DSO)	52.35	50.17	51.59	61.43	64.15	65.06	66.63	54.11	58.03	61.89	60.25
Days Inventory Outstanding (DIO)	238.59	223.87	224.12	215.22	184.16	192.75	219.41	191.57	199.47	198.44	205.11
Days Payable Outstanding (DPO)	47.96	35.57	33.37	51.55	54.29	61.13	58.76	35.55	50.94	54.02	43.80
Cash Conversion Cycle (CCC)	242.98	238.47	242.33	225.10	194.01	196.69	227.27	210.13	206.56	206.31	221.56
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	1,105	1,414	1,403	2,651	2,591	2,566	2,449	2,808	2,948	2,945	3,242
Invested Capital Turnover	0.78	0.70	0.70	0.59	0.56	0.59	0.55	0.59	0.54	0.52	0.52
Increase / (Decrease) in Invested Capital	168	308	-11	1,249	-60	-25	-117	359	141	-3.29	297
Enterprise Value (EV)	2,336	3,169	3,770	5,445	5,057	6,153	6,555	6,797	5,827	4,762	3,447
Market Capitalization	1,778	2,507	3,207	3,756	3,842	5,004	5,471	5,674	4,683	3,405	1,750
Book Value per Share	$21.48	$20.32	$22.46	$12.26	$16.15	$16.50	$17.98	$19.89	$21.60	$20.31	$20.03
Tangible Book Value per Share	($2.19)	($9.86)	($6.21)	($14.47)	($7.40)	($6.63)	($4.83)	($5.60)	($4.32)	($6.85)	($9.84)
Total Capital	1,334	1,466	1,505	2,826	2,730	2,765	3,069	3,321	3,405	3,254	3,515
Total Debt	630	714	665	1,864	1,354	1,348	1,554	1,637	1,601	1,666	1,970
Total Long-Term Debt	626	700	665	1,781	1,332	1,303	1,408	1,592	1,563	1,652	1,363
Net Debt	558	662	563	1,689	1,215	1,149	1,084	1,123	1,144	1,357	1,696
Capital Expenditures (CapEx)	38	32	47	43	77	70	35	48	31	67	104
Debt-free, Cash-free Net Working Capital (DFCFNWC)	335	262	270	381	396	373	512	345	422	456	493
Debt-free Net Working Capital (DFNWC)	407	314	372	556	535	572	982	859	879	766	767
Net Working Capital (NWC)	403	299	372	473	513	527	836	814	841	751	160
Net Nonoperating Expense (NNE)	20	13	21	190	57	28	83	-14	21	25	27
Net Nonoperating Obligations (NNO)	401	662	563	1,689	1,215	1,149	934	1,123	1,144	1,357	1,696
Total Depreciation and Amortization (D&A)	49	61	75	92	117	115	128	120	125	130	146
Debt-free, Cash-free Net Working Capital to Revenue	42.09%	29.63%	27.17%	32.07%	26.91%	24.58%	37.34%	22.38%	27.10%	29.61%	30.62%
Debt-free Net Working Capital to Revenue	51.09%	35.54%	37.45%	46.79%	36.34%	37.68%	71.61%	55.67%	56.41%	49.66%	47.60%
Net Working Capital to Revenue	50.62%	33.91%	37.45%	39.83%	34.81%	34.72%	60.95%	52.75%	53.96%	48.72%	9.91%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$0.47	($0.05)	$1.00	$0.84	$0.73	$0.59	$1.58	$2.00	$2.18	$0.85	($0.09)
Adjusted Weighted Average Basic Shares Outstanding	71.72M	68.99M	74.39M	76.90M	82.86M	85.64M	84.65M	84.70M	83.00M	80.09M	77.01M
Adjusted Diluted Earnings per Share	$0.47	($0.05)	$0.94	$0.82	$0.72	$0.58	$1.57	$1.98	$2.16	$0.84	($0.09)
Adjusted Weighted Average Diluted Shares Outstanding	72.89M	71.35M	79.19M	79.12M	84.00M	86.49M	85.23M	85.49M	83.52M	80.34M	77.01M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	72.48M	74.00M	74.82M	78.49M	85.23M	84.44M	84.37M	83.24M	81.64M	78.22M	77.22M
Normalized Net Operating Profit after Tax (NOPAT)	54	56	95	31	78	78	106	155	202	93	20
Normalized NOPAT Margin	6.78%	6.31%	9.59%	2.64%	5.28%	5.16%	7.72%	10.07%	12.95%	6.05%	1.23%
Pre Tax Income Margin	5.72%	6.87%	9.11%	0.96%	3.90%	3.96%	6.82%	13.92%	13.73%	5.26%	-1.13%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	3.07	3.58	4.50	1.32	1.84	1.91	2.18	5.13	5.07	2.24	0.46
NOPAT to Interest Expense	2.46	0.38	3.69	7.28	1.82	1.45	3.03	3.08	4.07	1.81	0.28
EBIT Less CapEx to Interest Expense	1.32	2.22	2.68	0.08	0.65	0.63	1.68	4.17	4.44	0.94	-1.02
NOPAT Less CapEx to Interest Expense	0.72	-0.98	1.86	6.04	0.62	0.16	2.54	2.13	3.44	0.51	-1.20
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	74.69%	0.00%	69.23%	405.96%	-755.63%

This table displays calculated financial ratios and metrics derived from Integra LifeSciences' official financial filings.

Metric	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025
Period end date	12/31/2022	3/31/2023	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	-1.85%	1.12%	-4.16%	-0.72%	-0.25%	-3.14%	9.68%	-0.42%	11.49%	3.74%	-0.61%
EBITDA Growth	10.48%	-12.63%	-52.11%	-40.70%	-31.57%	-50.12%	-17.83%	-47.06%	7.30%	-35.07%	-1,396.32%
EBIT Growth	14.92%	-23.84%	-80.03%	-60.40%	-46.99%	-91.12%	-112.89%	-122.31%	-3.75%	-566.34%	-32,225.38%
NOPAT Growth	9.64%	-23.38%	-73.68%	-49.55%	-55.71%	-90.63%	-115.50%	-120.48%	23.98%	-490.94%	-16,825.52%
Net Income Growth	16.66%	-26.37%	-90.66%	-60.94%	-62.54%	-113.54%	-396.41%	-154.85%	-2.02%	-670.89%	-3,803.19%
EPS Growth	18.87%	-25.64%	-90.74%	-60.00%	-58.73%	-113.79%	-420.00%	-158.33%	-3.85%	-725.00%	-3,843.75%
Operating Cash Flow Growth	23.18%	-41.02%	-57.46%	-60.81%	-31.15%	-39.76%	42.87%	-16.01%	-13.63%	-171.45%	-77.92%
Free Cash Flow Firm Growth	72.51%	-171.52%	-2,266.04%	-4,040.08%	133.15%	103.36%	-47.53%	60.07%	-1,047.17%	-5,159.43%	132.61%
Invested Capital Growth	5.01%	7.59%	7.16%	8.08%	-0.11%	-0.11%	9.10%	2.42%	10.07%	9.95%	-13.84%
Revenue Q/Q Growth	3.33%	-4.32%	0.11%	0.30%	3.82%	-7.09%	13.37%	-8.93%	16.23%	-13.55%	8.61%
EBITDA Q/Q Growth	3.45%	-31.25%	-37.01%	32.38%	19.38%	-49.89%	3.76%	-14.70%	141.92%	-69.67%	-2,171.51%
EBIT Q/Q Growth	5.05%	-47.39%	-67.31%	119.16%	40.63%	-91.19%	-147.47%	-279.27%	706.67%	-142.70%	-3,190.20%
NOPAT Q/Q Growth	1.30%	-47.09%	-53.78%	103.65%	-11.08%	-88.80%	-176.41%	-169.07%	638.42%	-135.32%	-3,208.21%
Net Income Q/Q Growth	6.07%	-54.24%	-82.73%	365.99%	1.73%	-116.54%	-277.99%	13.76%	281.71%	-230.15%	-1,813.86%
EPS Q/Q Growth	5.00%	-53.97%	-82.76%	380.00%	8.33%	-115.38%	-300.00%	12.50%	278.57%	-232.00%	-1,812.12%
Operating Cash Flow Q/Q Growth	24.92%	-69.35%	8.12%	-5.34%	119.46%	-73.18%	156.42%	-44.35%	125.66%	-122.19%	179.23%
Free Cash Flow Firm Q/Q Growth	-1,812.72%	-112.08%	-2.56%	-5.77%	114.41%	-78.48%	-4,598.95%	71.37%	-241.77%	-14.93%	129.00%
Invested Capital Q/Q Growth	6.99%	0.53%	-0.06%	0.54%	-1.12%	0.53%	9.16%	-5.62%	6.27%	0.43%	-14.47%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	62.83%	61.15%	54.30%	57.10%	57.05%	56.07%	54.02%	52.58%	56.27%	50.81%	50.37%
EBITDA Margin	25.88%	18.59%	11.70%	15.44%	17.75%	9.57%	8.76%	8.21%	17.08%	5.99%	-114.30%
Operating Margin	17.04%	9.55%	3.28%	6.95%	9.08%	1.07%	-0.72%	-2.14%	8.05%	-4.05%	-123.36%
EBIT Margin	18.04%	9.92%	3.24%	7.08%	9.59%	0.91%	-0.38%	-1.59%	8.28%	-4.09%	-123.82%
Profit (Net Income) Margin	13.30%	6.36%	1.10%	5.10%	5.00%	-0.89%	-2.97%	-2.81%	4.39%	-6.61%	-116.47%
Tax Burden Percent	82.46%	81.36%	109.41%	104.77%	68.73%	62.73%	81.67%	52.52%	86.22%	84.21%	91.17%
Interest Burden Percent	89.44%	78.84%	30.97%	68.76%	75.82%	-155.93%	953.83%	337.23%	61.53%	192.03%	103.17%
Effective Tax Rate	17.54%	18.64%	-9.41%	-4.77%	31.27%	0.00%	0.00%	0.00%	13.78%	0.00%	0.00%
Return on Invested Capital (ROIC)	7.61%	4.24%	1.94%	3.92%	3.26%	0.39%	-0.26%	-0.78%	3.61%	-1.48%	-46.55%
ROIC Less NNEP Spread (ROIC-NNEP)	7.34%	3.80%	1.14%	3.23%	2.87%	-0.07%	-0.95%	-1.12%	2.87%	-2.42%	-53.82%
Return on Net Nonoperating Assets (RNNOA)	4.77%	2.81%	0.81%	2.38%	2.12%	-0.06%	-0.88%	-1.06%	2.80%	-2.39%	-72.04%
Return on Equity (ROE)	12.38%	7.05%	2.75%	6.30%	5.38%	0.33%	-1.13%	-1.83%	6.41%	-3.88%	-118.59%
Cash Return on Invested Capital (CROIC)	2.12%	-0.58%	-1.59%	-3.43%	3.27%	2.44%	-6.91%	-1.72%	-8.94%	-9.28%	3.22%
Operating Return on Assets (OROA)	7.32%	4.18%	1.33%	2.89%	3.85%	0.36%	-0.15%	-0.64%	3.41%	-1.63%	-51.87%
Return on Assets (ROA)	5.40%	2.68%	0.45%	2.08%	2.01%	-0.35%	-1.18%	-1.13%	1.81%	-2.64%	-48.79%
Return on Common Equity (ROCE)	12.38%	7.05%	2.75%	6.30%	5.38%	0.33%	-1.13%	-1.83%	6.41%	-3.88%	-118.59%
Return on Equity Simple (ROE_SIMPLE)	0.00%	10.26%	7.80%	6.39%	0.00%	2.52%	1.54%	-0.43%	0.00%	-1.90%	0.00%
Net Operating Profit after Tax (NOPAT)	56	30	14	28	25	2.77	-2.12	-5.71	31	-11	-359
NOPAT Margin	14.05%	7.77%	3.59%	7.29%	6.24%	0.75%	-0.51%	-1.50%	6.94%	-2.83%	-86.35%
Net Nonoperating Expense Percent (NNEP)	0.26%	0.44%	0.80%	0.69%	0.40%	0.46%	0.69%	0.34%	0.74%	0.93%	7.27%
Return On Investment Capital (ROIC_SIMPLE)	1.64%	0.90%	0.42%	0.86%	0.76%	0.08%	-0.06%	-0.17%	0.87%	-0.31%	-11.81%
Cost of Revenue to Revenue	37.17%	38.85%	45.70%	42.90%	42.95%	43.93%	45.98%	47.42%	43.73%	49.19%	49.63%
SG&A Expenses to Revenue	38.17%	43.76%	43.25%	42.35%	41.09%	44.95%	46.74%	46.53%	40.33%	47.43%	43.28%
R&D to Revenue	6.73%	7.02%	6.97%	6.95%	6.12%	7.31%	7.12%	7.20%	7.05%	6.46%	6.50%
Operating Expenses to Revenue	45.79%	51.59%	51.02%	50.14%	47.97%	55.00%	54.75%	54.72%	48.22%	54.86%	173.72%
Earnings before Interest and Taxes (EBIT)	72	38	12	27	38	3.35	-1.59	-6.04	37	-16	-515
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	103	71	45	59	70	35	37	31	76	23	-475
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	2.60	2.80	2.00	1.97	2.14	1.73	1.50	0.93	1.13	1.11	0.92
Price to Tangible Book Value (P/TBV)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Price to Revenue (P/Rev)	3.01	3.00	2.18	2.02	2.21	1.81	1.47	0.90	1.09	1.05	0.59
Price to Earnings (P/E)	25.94	27.27	25.66	30.83	50.26	68.88	97.10	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	3.86%	3.67%	3.90%	3.24%	1.99%	1.45%	1.03%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	1.98	2.02	1.57	1.51	1.62	1.40	1.24	0.96	1.06	1.05	0.97
Enterprise Value to Revenue (EV/Rev)	3.74	3.83	3.01	2.92	3.09	2.70	2.55	1.88	2.14	2.11	1.66
Enterprise Value to EBITDA (EV/EBITDA)	15.47	16.31	14.62	16.25	19.44	19.74	19.82	16.92	19.27	20.60	0.00
Enterprise Value to EBIT (EV/EBIT)	23.16	24.93	24.43	30.26	41.32	51.15	59.72	86.98	106.52	256.70	0.00
Enterprise Value to NOPAT (EV/NOPAT)	28.89	31.01	30.51	36.31	51.10	59.83	71.87	145.61	173.30	547.41	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	22.03	24.26	22.34	27.07	34.02	31.91	28.19	21.39	26.64	33.50	38.08
Enterprise Value to Free Cash Flow (EV/FCFF)	95.42	0.00	0.00	0.00	49.36	57.13	0.00	0.00	0.00	0.00	27.83
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.89	0.95	0.94	1.06	1.05	1.27	1.30	1.19	1.27	1.32	1.93
Long-Term Debt to Equity	0.87	0.95	0.89	1.01	1.04	1.26	1.28	0.79	0.88	0.91	1.33
Financial Leverage	0.65	0.74	0.71	0.74	0.74	0.81	0.93	0.94	0.97	0.99	1.34
Leverage Ratio	2.20	2.25	2.25	2.28	2.26	2.39	2.44	2.52	2.50	2.60	3.01
Compound Leverage Factor	1.97	1.78	0.70	1.57	1.71	-3.73	23.28	8.49	1.54	5.00	3.10
Debt to Total Capital	47.01%	48.80%	48.55%	51.44%	51.21%	55.91%	56.53%	54.28%	56.04%	56.81%	65.81%
Short-Term Debt to Total Capital	1.12%	0.00%	2.92%	2.63%	0.45%	0.53%	0.69%	18.07%	17.27%	17.36%	20.19%
Long-Term Debt to Total Capital	45.89%	48.80%	45.63%	48.82%	50.76%	55.37%	55.84%	36.21%	38.77%	39.45%	45.63%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	52.99%	51.20%	51.45%	48.56%	48.79%	44.09%	43.47%	45.72%	43.96%	43.19%	34.19%
Debt to EBITDA	4.25	4.36	5.00	6.03	6.80	9.67	9.90	10.40	11.02	12.04	-5.79
Net Debt to EBITDA	3.04	3.52	4.02	5.04	5.54	6.51	8.43	8.80	9.49	10.40	-5.06
Long-Term Debt to EBITDA	4.15	4.36	4.70	5.72	6.74	9.58	9.78	6.94	7.62	8.36	-4.02
Debt to NOPAT	7.94	8.28	10.43	13.48	17.88	29.32	35.89	89.51	99.06	319.99	-5.71
Net Debt to NOPAT	5.67	6.69	8.40	11.27	14.56	19.72	30.55	75.76	85.30	276.37	-4.98
Long-Term Debt to NOPAT	7.75	8.28	9.80	12.79	17.73	29.04	35.46	59.71	68.53	222.21	-3.96
Altman Z-Score	2.38	2.39	1.94	1.86	1.96	1.70	1.48	1.08	1.22	1.16	0.43
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	3.62	3.65	2.78	2.89	3.45	4.68	3.39	1.20	1.17	1.21	1.23
Quick Ratio	2.24	1.99	1.50	1.49	1.85	2.99	1.73	0.58	0.59	0.57	0.58
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-85	-180	-184	-195	28	6.04	-272	-78	-266	-306	89
Operating Cash Flow to CapEx	590.30%	190.86%	181.88%	204.69%	239.45%	101.88%	136.00%	75.85%	171.42%	-38.92%	44.27%
Free Cash Flow to Firm to Interest Expense	-6.57	-14.84	-14.77	-14.91	2.04	0.44	-14.57	-4.02	-14.00	-16.24	4.21
Operating Cash Flow to Interest Expense	6.62	2.16	2.27	2.05	4.27	1.16	2.17	1.16	2.67	-0.60	0.42
Operating Cash Flow Less CapEx to Interest Expense	5.50	1.03	1.02	1.05	2.49	0.02	0.57	-0.37	1.11	-2.14	-0.53
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.41	0.42	0.41	0.41	0.40	0.39	0.40	0.40	0.41	0.40	0.42
Accounts Receivable Turnover	6.29	6.40	6.23	6.11	5.90	6.18	5.91	6.20	6.06	6.58	5.84
Inventory Turnover	1.83	1.75	1.83	1.87	1.84	1.78	1.78	1.76	1.78	1.78	1.73
Fixed Asset Turnover	5.00	5.00	4.99	4.98	4.73	4.63	4.53	4.41	4.32	4.23	4.01
Accounts Payable Turnover	7.17	5.89	7.31	7.28	6.76	6.48	6.65	8.24	8.33	8.13	7.67
Days Sales Outstanding (DSO)	58.03	57.02	58.58	59.69	61.89	59.07	61.72	58.84	60.25	55.45	62.53
Days Inventory Outstanding (DIO)	199.47	209.14	198.99	194.90	198.44	205.29	205.59	207.79	205.11	205.28	210.57
Days Payable Outstanding (DPO)	50.94	61.93	49.94	50.15	54.02	56.36	54.90	44.29	43.80	44.91	47.56
Cash Conversion Cycle (CCC)	206.56	204.23	207.64	204.44	206.31	208.01	212.41	222.33	221.56	215.82	225.54
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	2,948	2,964	2,963	2,979	2,945	2,961	3,232	3,051	3,242	3,256	2,785
Invested Capital Turnover	0.54	0.55	0.54	0.54	0.52	0.52	0.51	0.52	0.52	0.52	0.54
Increase / (Decrease) in Invested Capital	141	209	198	223	-3.29	-3.26	270	72	297	295	-447
Enterprise Value (EV)	5,827	5,976	4,648	4,508	4,762	4,134	3,994	2,939	3,447	3,430	2,700
Market Capitalization	4,683	4,687	3,369	3,109	3,405	2,771	2,296	1,410	1,750	1,698	954
Book Value per Share	$21.60	$20.52	$20.55	$19.40	$20.31	$20.56	$19.47	$19.61	$20.03	$19.74	$13.37
Tangible Book Value per Share	($4.32)	($5.82)	($5.54)	($6.44)	($6.85)	($5.98)	($10.03)	($10.37)	($9.84)	($9.96)	($9.85)
Total Capital	3,405	3,272	3,272	3,252	3,254	3,624	3,529	3,328	3,515	3,529	3,038
Total Debt	1,601	1,597	1,589	1,673	1,666	2,026	1,995	1,807	1,970	2,005	2,000
Total Long-Term Debt	1,563	1,597	1,493	1,588	1,652	2,007	1,971	1,205	1,363	1,392	1,386
Net Debt	1,144	1,289	1,279	1,399	1,357	1,363	1,698	1,529	1,696	1,731	1,746
Capital Expenditures (CapEx)	14	14	16	13	25	15	30	30	30	29	20
Debt-free, Cash-free Net Working Capital (DFCFNWC)	422	440	460	483	456	470	511	511	493	528	573
Debt-free Net Working Capital (DFNWC)	879	747	769	757	766	1,133	808	788	767	801	826
Net Working Capital (NWC)	841	747	674	672	751	1,113	784	187	160	189	213
Net Nonoperating Expense (NNE)	2.99	5.37	9.50	8.36	4.94	6.06	10	4.99	11	14	125
Net Nonoperating Obligations (NNO)	1,144	1,289	1,279	1,399	1,357	1,363	1,698	1,529	1,696	1,731	1,746
Total Depreciation and Amortization (D&A)	31	33	32	32	32	32	38	37	39	39	40
Debt-free, Cash-free Net Working Capital to Revenue	27.10%	28.16%	29.78%	31.32%	29.61%	30.70%	32.64%	32.64%	30.62%	32.52%	35.32%
Debt-free Net Working Capital to Revenue	56.41%	47.84%	49.79%	49.07%	49.66%	74.05%	51.59%	50.38%	47.60%	49.34%	50.96%
Net Working Capital to Revenue	53.96%	47.84%	43.60%	43.53%	48.72%	72.78%	50.05%	11.95%	9.91%	11.62%	13.14%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$0.65	$0.30	$0.05	$0.24	$0.26	($0.04)	($0.16)	($0.14)	$0.25	($0.33)	($6.31)
Adjusted Weighted Average Basic Shares Outstanding	83.00M	81.87M	80.97M	79.69M	80.09M	77.74M	77.41M	76.45M	77.01M	76.46M	76.70M
Adjusted Diluted Earnings per Share	$0.63	$0.29	$0.05	$0.24	$0.26	($0.04)	($0.16)	($0.14)	$0.25	($0.33)	($6.31)
Adjusted Weighted Average Diluted Shares Outstanding	83.52M	82.32M	81.15M	79.81M	80.34M	77.74M	77.41M	76.45M	77.01M	76.46M	76.70M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	81.64M	81.90M	81.40M	78.18M	78.22M	78.80M	77.58M	77.16M	77.22M	77.71M	77.91M
Normalized Net Operating Profit after Tax (NOPAT)	56	30	8.75	19	25	2.77	-2.12	-5.71	31	-11	-0.92
Normalized NOPAT Margin	14.05%	7.77%	2.30%	4.87%	6.24%	0.75%	-0.51%	-1.50%	6.94%	-2.83%	-0.22%
Pre Tax Income Margin	16.13%	7.82%	1.00%	4.87%	7.27%	-1.42%	-3.63%	-5.35%	5.09%	-7.85%	-127.75%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	5.57	3.12	0.99	2.07	2.77	0.25	-0.09	-0.31	1.93	-0.83	-24.46
NOPAT to Interest Expense	4.34	2.45	1.10	2.13	1.80	0.20	-0.11	-0.29	1.62	-0.58	-17.06
EBIT Less CapEx to Interest Expense	4.45	1.99	-0.26	1.07	0.98	-0.89	-1.68	-1.84	0.37	-2.37	-25.41
NOPAT Less CapEx to Interest Expense	3.22	1.31	-0.15	1.13	0.02	-0.93	-1.71	-1.82	0.06	-2.11	-18.01
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	69.23%	87.27%	114.27%	272.67%	405.96%	310.68%	740.02%	-764.06%	-755.63%	0.00%	-0.54%

Key Financial Trends

Integra LifeSciences (NASDAQ: IART) has shown varied financial performance over the last several years through Q2 2025, with notable fluctuations in profitability and cash flows.

Positive financial trends and data points:

Operating revenue for the recent quarter Q2 2025 was $415.6 million, showing continued sales volume.
Gross profit remained positive in Q2 2025 at $209.3 million despite challenging conditions.
Cash and equivalents remained healthy at $217.9 million at Q2 2025 end, ensuring liquidity.
Depreciation expenses consistently add non-cash charges helpful for cash flow (approx. $35-38 million per quarter).
Long term tangible assets like Property, Plant & Equipment have grown to $434.8 million by Q2 2025, indicating ongoing investment.
Total equity remains significant, though reduced to about $1.04 billion by Q2 2025, still providing a solid capital base.
Cash flow from operating activities was positive $8.9 million in Q2 2025, reflecting cash generation after core operations.
Research and development spending remains stable around $27 million per quarter, supporting future pipelines.
The company experienced positive operating income and net income in several quarters from 2022 to early 2024, indicating past profitability capability.
Weighted average shares outstanding have been relatively stable, helping maintain EPS comparability.

Neutral observations:

The company maintains a significant level of goodwill and intangible assets (over $1.8 billion combined), largely unchanged, reflecting acquisitions and intellectual property.
Total liabilities are sizeable at about $2.63 billion as of Q2 2025, consistent with prior years—typical for Life Sciences companies with debt financing.
Capital lease obligations remain around $159 million, reflecting ongoing commitments.
Interest expense consistently around $18–21 million per quarter, suggesting steady financing costs.
Cash outflows for purchasing property, plant & equipment and investments indicate ongoing capital allocation but raise cash burn concerns if not offset.

Negative financial trends and warning signs:

Q2 2025 reported a large loss of $484 million, a steep decline compared to profitable quarters in 2023 and early 2024, driven largely by a $511 million impairment charge.
Operating expenses spiked dramatically in Q2 2025 to $722 million, largely due to the one-time impairment, negatively impacting operating income.
Net cash from financing activities was negative $21.1 million in Q2 2025, reducing cash reserves.
Inventory levels are high at $465 million in Q2 2025, which might indicate overstocking or slower sales.
The company’s net income and earnings per share have turned negative in several recent quarters, with Q2 2025 EPS at -$6.31 indicating severe profitability issues.
Net cash from operating activities was positive but small ($8.9 million in Q2 2025) compared to the scale of losses and investments, possibly a concern for operational cash generation sustainability.
Total liabilities have generally increased, reaching over $2.6 billion, and long-term debt remains elevated at approximately $1.2 billion, suggesting financial leverage risk.
There is continuous repayment of debt but also periodic issuance suggesting refinancing and possibly liquidity management pressure.
The fluctuations in net income and cash flows, including significant impairment charges, indicate potential volatility in future earnings.
Accumulated other comprehensive loss of $30.9 million in Q2 2025 shows some losses in non-operating areas.

Summary: Integra LifeSciences has a history of moderate profitability and solid revenue growth along with significant investments into fixed assets and R&D. However, the large impairment charge in Q2 2025 has drastically impacted profitability and operating expenses, resulting in a substantial quarterly loss. Cash flows from operating activities remain positive though relatively small against expenses and liabilities. The company’s high debt level and inventory require attention, as these may affect financial stability going forward. Investors should watch for the company’s ability to manage costs, return to profitability, and improve operational cash flow in coming quarters.

08/25/25 06:15 PMAI Generated. May Contain Errors.

Frequently Asked Questions About Integra LifeSciences' Financials

When does Integra LifeSciences' fiscal year end?

According to the most recent income statement we have on file, Integra LifeSciences' financial year ends in December. Their financial year 2024 ended on December 31, 2024.

How has Integra LifeSciences' net income changed over the last 10 years?

Integra LifeSciences' net income appears to be on an upward trend, with a most recent value of -$6.94 million in 2024, falling from $34.00 million in 2014. The previous period was $67.74 million in 2023. See Integra LifeSciences' forecast for analyst expectations on what’s next for the company.

What is Integra LifeSciences' operating income?

Integra LifeSciences' total operating income in 2024 was $28.41 million, based on the following breakdown:

Total Gross Profit: $882.06 million
Total Operating Expenses: $853.65 million

How has Integra LifeSciences' revenue changed over the last 10 years?

Over the last 10 years, Integra LifeSciences' total revenue changed from $796.72 million in 2014 to $1.61 billion in 2024, a change of 102.1%.

How much debt does Integra LifeSciences have?

Integra LifeSciences' total liabilities were at $2.49 billion at the end of 2024, a 13.6% increase from 2023, and a 182.2% increase since 2014.

How much cash does Integra LifeSciences have?

In the past 10 years, Integra LifeSciences' cash and equivalents has ranged from $48.13 million in 2015 to $513.45 million in 2021, and is currently $246.38 million as of their latest financial filing in 2024.

How has Integra LifeSciences' book value per share changed over the last 10 years?

Over the last 10 years, Integra LifeSciences' book value per share changed from 21.48 in 2014 to 20.03 in 2024, a change of -6.8%.

Related Companies

This page (NASDAQ:IART) was last updated on 8/25/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Integra LifeSciences (IART) Financials

Key Financial Trends

Frequently Asked Questions About Integra LifeSciences' Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Integra LifeSciences (IART) Financials

Annual Income Statements for Integra LifeSciences

Quarterly Income Statements for Integra LifeSciences

Annual Cash Flow Statements for Integra LifeSciences

Quarterly Cash Flow Statements for Integra LifeSciences

Annual Balance Sheets for Integra LifeSciences

Quarterly Balance Sheets for Integra LifeSciences

Annual Metrics And Ratios for Integra LifeSciences

Quarterly Metrics And Ratios for Integra LifeSciences

Key Financial Trends

Frequently Asked Questions About Integra LifeSciences' Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools